Human Leukocyte Antigen Haplotypes in the Genetic Control of Immune Response to Measles-Mumps-Rubella Vaccine

To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12–18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglo...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 193; no. 5; pp. 655 - 663
Main Authors Ovsyannikova, Inna G., Pankratz, V. Shane, Vierkant, Robert A., Jacobson, Robert M., Poland, Gregory A.
Format Journal Article
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.03.2006
University of Chicago Press
Oxford University Press
Subjects
Online AccessGet full text
ISSN0022-1899
1537-6613
DOI10.1086/500144

Cover

Loading…
Abstract To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12–18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus–specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus–specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level
AbstractList To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.
To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.
To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P=.08) and mumps (P=.03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P=.02) and mumps (P=.01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P=.01) and mumps virus (P=.006). The DRB1*15/16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P=.09) but low levels of IgG antibody to rubella virus (P=.02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P=.01) and rubella (P=.002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P=.007) and cell-mediated (P=.01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*04-DQB1*03-DPB1*03 was associated with both lower rubella virus IgG antibody levels (P=.02) and higher rubella virus-specific lymphoproliferation (P=.002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level
To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P = .08) and mumps (P = .03) viral antigens. The A*26-Cw* 12-B*38 haplotype was associated with higher cellular immune responses to measles (P = .02) and mumps (P — .01) vaccine viruses. Subjects with the class II DRB1*03-DQB1*02-DPB1*04 haplotype had higher lymphoproliferative responses to measles virus (P = .01) and mumps virus (P = .006). The DRB1*15Z16-DQB1*06-DPB1*03 haplotype was associated with high levels of IgG antibody to measles virus (P = .09) but low levels of IgG antibody to rubella virus (P = .02), whereas DRB1*04-DQB1*03-DPB1*03 was associated with high lymphoproliferative responses to both measles (P = .01) and rubella (P = .002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P = .007) and cell-mediated (P = .01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1 *04-DQB 1*03-DPB 1*03 was associated with both lower rubella virus IgG antibody levels (P = .02) and higher rubella virus-specific lymphoproliferation (P = .002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.
To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR) vaccination, 346 children 12-18 years of age were studied. The class I A*29-Cw*16-B*44 haplotype was associated with lower levels of immunoglobulin G (IgG) antibody to both measles (P = .08) and mumps (P = .03) viral antigens. The A*26-Cw*12-B*38 haplotype was associated with higher cellular immune responses to measles (P = .02) and mumps (P= .01) vaccine viruses. Subjects with the class II DRB1*O3-DQB1*O2-DPB1*O4 haplotype had higher lymphoproliferative responses to measles virus (P = .01) and mumps virus (P = .006). The DRB1*15/16-DQB1*O6-DPB1*O3 haplotype was associated with high levels of IgG antibody to measles virus (P = .09) but low levels of IgG antibody to rubella virus (P = .02), whereas DRB1*O4-DQB1*O3-DPB1*O3 was associated with high lymphoproliferative responses to both measles (P = .01) and rubella (P = .002) vaccine viruses. A*26-Cw*12-B*38 was associated with both mumps virus-specific humoral (P = .007) and cell-mediated (P = .01) immune responses after 2 doses of MMR vaccine. Haplotype DRB1*O4-DQB1*O3-DPB1*O3 was associated with both lower rubella virus IgG antibody levels (P = .02) and higher rubella virus-specific lymphoproliferation (P = .002). Better characterization of such HLA profiles could inform and improve the design of novel epitope-rich vaccines and help to predict protective immune responses at the individual and population level.
Author Pankratz, V. Shane
Vierkant, Robert A.
Ovsyannikova, Inna G.
Jacobson, Robert M.
Poland, Gregory A.
Author_xml – sequence: 1
  givenname: Inna G.
  surname: Ovsyannikova
  fullname: Ovsyannikova, Inna G.
  organization: Mayo Vaccine Research Group
– sequence: 2
  givenname: V. Shane
  surname: Pankratz
  fullname: Pankratz, V. Shane
  organization: Department of Health Sciences Research
– sequence: 3
  givenname: Robert A.
  surname: Vierkant
  fullname: Vierkant, Robert A.
  organization: Department of Health Sciences Research
– sequence: 4
  givenname: Robert M.
  surname: Jacobson
  fullname: Jacobson, Robert M.
  organization: Mayo Vaccine Research Group
– sequence: 5
  givenname: Gregory A.
  surname: Poland
  fullname: Poland, Gregory A.
  email: poland.gregory@mayo.edu
  organization: Mayo Vaccine Research Group
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17591499$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16453260$$D View this record in MEDLINE/PubMed
BookMark eNqF0VGL1DAQB_AgJ97eqt9AiYI-WU2aNG0ez0VvD_YQ7lTEl5Bmp5q9NqlNAu63t6XrHhyIT_Mwv_zJzJyhE-cdIPSUkreUVOJdQQjl_AFa0IKVmRCUnaAFIXme0UrKU3QWwo4QwpkoH6FTKnjBckEWqFunTju8gXTrzT4CPnfR_gCH17pvfdz3ELB1OP4EfAEOojV45V0cfIt9gy-7LjnA1xB67wLg6PEV6NBCyK5S14fsOtXQthp_1cZYB4_Rw0a3AZ4c6hJ9-fjh82qdbT5dXK7ON5nhFYsZNHSraz6-MXyqVFJdmxoanXPgupBMa7qtCTeC1JRVpJAVg7IkjDaSVw1botdzbj_4XwlCVJ0NZvqJA5-CEqXIOSvEfyEtiaRsTF-il_fgzqfBjUOoPGdy3Cyf0p4fUKo72Kp-sJ0e9urvukfw6gB0MLptBu2MDXeuLCTlUo7uzezM4EMYoFHGRh3ttHltW0WJmq6u5qvfTXHkx8T78MUMfer_bZ7NZheiH46KkdHwqhz72dy3IcLvY18Pt-NaWVmo9bfvqqzEzfu1vFGC_QGo-8w9
CODEN JIDIAQ
CitedBy_id crossref_primary_10_1126_scitranslmed_aab4005
crossref_primary_10_1016_j_vaccine_2008_06_057
crossref_primary_10_1208_s12248_011_9281_x
crossref_primary_10_1186_1471_2172_11_48
crossref_primary_10_1016_j_vaccine_2011_05_068
crossref_primary_10_1371_journal_pone_0171261
crossref_primary_10_1016_j_vaccine_2012_12_026
crossref_primary_10_3389_fimmu_2020_01181
crossref_primary_10_1016_j_clim_2014_02_011
crossref_primary_10_1038_sj_clpt_6100415
crossref_primary_10_1016_j_cyto_2006_12_001
crossref_primary_10_1016_j_vaccine_2024_126527
crossref_primary_10_1089_omi_2011_0032
crossref_primary_10_1007_s13312_021_2165_y
crossref_primary_10_1016_j_vaccine_2017_02_013
crossref_primary_10_1016_j_vaccine_2009_01_080
crossref_primary_10_1098_rstb_2014_0341
crossref_primary_10_1128_CMR_00048_08
crossref_primary_10_1016_j_vaccine_2009_08_109
crossref_primary_10_3389_fimmu_2022_1054147
crossref_primary_10_1016_j_jinf_2010_06_012
crossref_primary_10_1016_j_vaccine_2007_01_020
crossref_primary_10_1111_sji_13266
crossref_primary_10_2217_pgs_09_25
crossref_primary_10_1016_j_paed_2009_08_019
crossref_primary_10_1016_j_smim_2013_04_007
crossref_primary_10_1093_infdis_jir167
crossref_primary_10_1097_FPC_0b013e32834df186
crossref_primary_10_1007_s00439_008_0511_y
crossref_primary_10_1016_j_vaccine_2011_08_058
crossref_primary_10_1080_21645515_2020_1849520
crossref_primary_10_1007_s00439_009_0720_z
crossref_primary_10_1371_journal_pone_0011806
crossref_primary_10_1016_j_vaccine_2011_02_071
crossref_primary_10_1517_14712598_8_11_1659
crossref_primary_10_1016_j_vaccine_2013_09_026
crossref_primary_10_1128_CVI_05652_11
crossref_primary_10_1128_JVI_00883_10
crossref_primary_10_1093_infdis_jir065
crossref_primary_10_1016_j_coi_2011_04_005
crossref_primary_10_1016_j_molmed_2015_10_005
crossref_primary_10_1016_j_vaccine_2011_08_060
crossref_primary_10_1016_j_vaccine_2012_01_038
crossref_primary_10_1111_j_1399_0039_2007_00986_x
crossref_primary_10_1371_journal_pone_0064813
crossref_primary_10_1371_journal_ppat_1002344
crossref_primary_10_1038_gene_2011_15
crossref_primary_10_1586_erv_12_134
crossref_primary_10_2174_0113816128280417231204085137
crossref_primary_10_1080_21645515_2019_1675458
crossref_primary_10_1038_s41467_021_22236_7
crossref_primary_10_1016_j_vaccine_2012_07_063
crossref_primary_10_1371_journal_pone_0062149
crossref_primary_10_1016_j_vaccine_2023_02_009
crossref_primary_10_1007_s00439_014_1449_x
crossref_primary_10_1542_peds_2007_1575
crossref_primary_10_1016_j_humimm_2021_09_006
crossref_primary_10_1007_s00439_014_1471_z
crossref_primary_10_1016_j_vaccine_2008_05_011
crossref_primary_10_1128_CMR_00084_18
crossref_primary_10_3390_v15040906
ContentType Journal Article
Copyright Copyright 2006 Infectious Diseases Society of America
2006 by the Infectious Diseases Society of America 2006
2006 INIST-CNRS
Copyright University of Chicago Press Mar 1, 2006
Copyright_xml – notice: Copyright 2006 Infectious Diseases Society of America
– notice: 2006 by the Infectious Diseases Society of America 2006
– notice: 2006 INIST-CNRS
– notice: Copyright University of Chicago Press Mar 1, 2006
DBID BSCLL
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7T5
7U9
8FD
FR3
H94
P64
RC3
7X8
DOI 10.1086/500144
DatabaseName Istex
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE
MEDLINE - Academic



Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1537-6613
EndPage 663
ExternalDocumentID 995463221
16453260
17591499
10_1086_500144
10.1086/500144
30086487
ark_67375_HXZ_786SBH9S_6
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: AI 48793
– fundername: NCRR NIH HHS
  grantid: MO1 RR00585
– fundername: NIAID NIH HHS
  grantid: AI 33144
GroupedDBID ---
-DZ
-~X
..I
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
123
1TH
29K
2AX
2WC
36B
4.4
48X
53G
5GY
5RE
5VS
5WD
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWTL
ABBHK
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPQP
ABPTD
ABQLI
ABQNK
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACGFO
ACGFS
ACGOD
ACHIC
ACPRK
ACUFI
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQVQM
ATGXG
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BSCLL
BTRTY
BVRKM
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
EBS
ECGQY
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H5~
HAR
HQ3
HTVGU
HW0
HZ~
IH2
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
MHKGH
MJL
ML0
MVM
N4W
N9A
NEJ
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TR2
W2D
W8F
WH7
X7H
X7M
YAYTL
YKOAZ
YXANX
ZGI
~91
AAYOK
AASNB
ADACV
ADJQC
ADRIX
AFXEN
DOOOF
ESX
JSODD
M49
1KJ
3O-
41~
AAFWJ
AAPGJ
AAWDT
AAYXX
ABDPE
ABSMQ
ACFRR
ACPQN
ACUTJ
ACVCV
ACZBC
ADMTO
AEKPW
AFFQV
AFHKK
AFQQW
AFSHK
AGKRT
AGMDO
AHGBF
AI.
AJDVS
APJGH
AQDSO
AQKUS
AVNTJ
BZKNY
CITATION
EIHJH
H13
MBLQV
OBFPC
O~Y
P0-
TMA
VH1
Y6R
ZE2
ZXP
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
VXZ
YIF
K9.
NAPCQ
7T5
7U9
8FD
FR3
H94
P64
RC3
7X8
ID FETCH-LOGICAL-c483t-ef1dab4accc4ab4a191abcbefa24e4a593aa1db04c60b13805983e77031f948f3
ISSN 0022-1899
IngestDate Fri Sep 05 00:40:30 EDT 2025
Fri Sep 05 10:47:17 EDT 2025
Fri Jul 25 19:25:27 EDT 2025
Wed Feb 19 01:43:37 EST 2025
Mon Jul 21 09:16:15 EDT 2025
Tue Jul 01 03:23:48 EDT 2025
Thu Apr 24 23:04:51 EDT 2025
Wed Sep 11 04:50:41 EDT 2024
Fri Jun 20 02:31:52 EDT 2025
Tue Aug 05 16:48:09 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Infection
Rubella
HLA-System
Immune response
Microbiology
Viral disease
Measles
Vaccine
Mumps
Genetic determinism
Haplotype
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c483t-ef1dab4accc4ab4a191abcbefa24e4a593aa1db04c60b13805983e77031f948f3
Notes istex:B1991BBA134AFCCAE4B7FA58906915B09427363B
ark:/67375/HXZ-786SBH9S-6
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-General Information-1
content type line 14
ObjectType-Feature-3
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/jid/article-pdf/193/5/655/18010567/193-5-655.pdf
PMID 16453260
PQID 223900446
PQPubID 41591
PageCount 9
ParticipantIDs proquest_miscellaneous_67624356
proquest_miscellaneous_17091398
proquest_journals_223900446
pubmed_primary_16453260
pascalfrancis_primary_17591499
crossref_citationtrail_10_1086_500144
crossref_primary_10_1086_500144
oup_primary_10_1086_500144
jstor_primary_30086487
istex_primary_ark_67375_HXZ_786SBH9S_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2006-03-01
PublicationDateYYYYMMDD 2006-03-01
PublicationDate_xml – month: 03
  year: 2006
  text: 2006-03-01
  day: 01
PublicationDecade 2000
PublicationPlace Chicago, IL
PublicationPlace_xml – name: Chicago, IL
– name: United States
– name: Oxford
PublicationTitle The Journal of infectious diseases
PublicationTitleAbbrev The Journal of Infectious Diseases
PublicationTitleAlternate The Journal of Infectious Diseases
PublicationYear 2006
Publisher The University of Chicago Press
University of Chicago Press
Oxford University Press
Publisher_xml – name: The University of Chicago Press
– name: University of Chicago Press
– name: Oxford University Press
SSID ssj0004367
Score 2.1358876
Snippet To elucidate the contribution of human leukocyte antigen (HLA) haplotypes and their genotypic combinations to immune status after measles-mumps-rubella (MMR)...
SourceID proquest
pubmed
pascalfrancis
crossref
oup
jstor
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 655
SubjectTerms Adolescent
Antibodies
Antibodies, Viral - blood
Applied microbiology
Biological and medical sciences
Child
Fundamental and applied biological sciences. Psychology
Haplotypes
HLA antigens
HLA Antigens - genetics
HLA Antigens - immunology
Human viral diseases
Humans
Immune response
Immunity, Cellular
Immunoglobulin G - blood
Infectious diseases
Lymphocyte Activation
Lymphocytes - immunology
Measels mumps rubella vaccine
Measles
Measles virus
Measles virus - immunology
Measles-Mumps-Rubella Vaccine - immunology
Medical sciences
Microbiology
Mumps
Mumps virus
Mumps virus - immunology
Rubella
Rubella virus
Statistics as Topic
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye
Viruses
Title Human Leukocyte Antigen Haplotypes in the Genetic Control of Immune Response to Measles-Mumps-Rubella Vaccine
URI https://api.istex.fr/ark:/67375/HXZ-786SBH9S-6/fulltext.pdf
https://www.jstor.org/stable/30086487
https://www.ncbi.nlm.nih.gov/pubmed/16453260
https://www.proquest.com/docview/223900446
https://www.proquest.com/docview/17091398
https://www.proquest.com/docview/67624356
Volume 193
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJtAkhGAw1g2GH4CXKVPSOE7yCAioKhUedlHFS2QntoC2SdWkFeWd_83xJZexVQJe2ip2k7TfZ-ccn8_nIPQykoySjHJlubkOkZ7v8MAVjqSSZ4GQZKDF4-NPdHhJRpNg0uv96qiWVhU_S3_euq_kf1CFY4Cr2iX7D8g2J4UD8BnwhVdAGF7_CmOzAj8Tq2mRbioVCKhUcs3Tr2wxK9TialnLGOGo2q3YKNNVogi1M0QVTdEiWV1BYy5YORPg_ALGpbNcqaAEO12ztIm-f2_JNermnDCKrlVZB3waS_3zutyoskjTYs3MfJSzTj0vlk-BgnoR-0olj26D_FfwvJ4ykxXByL_bZdcRTON13XPbNv5z-aLWb3W2E3iRqZLUTMmmaqLlXtCZYKlJ6ntj4nd1HCpQHh_pdgDAFnMNP_iFAdiqbvvga-SIddMdtDsIQx3t_zhplULEp2GddF7daadElbmgyjxrT3HNvNlVI_VHrXStt1DeX7ASxp80hVO2ezbawrl4iB5YPPEbw7NHqCfyfXTXFCvd7KN7YyvDeIzmmni4IR62xMMt8fC3HAPxsCUetsTDhcSGeLgmHq4KfCvxsCXeE3T54f3Fu6Fj63Y4KYn8yhHSyxgn0Ccl6t2LPcZTLiQbEEFYEPuMeRl3SUpd7vkRWPiRL0JVSUHGJJL-AdrJi1wcIuxLmXEwicExyIifykj70wMifY-F4Az30av6705Sm9Re1VaZJVpcEdHEINRHL5p-C5PG5UaP1xqtppktp0r0GAbJcPIlCSN6_nYYnye0jw40nE1HXy0LgN_fR0eA79bTn1yDve0WBrFHYvglxzUPEjvFlAnY7rGWXMD9N60w_6ugHoxIGNbwfZ3ZN9reg4K9A04RnOOpoVd7bUvao60tx2ivHbTP0E61XInnYIVX_ESPkd8Lgd0D
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+leukocyte+antigen+haplotypes+in+the+genetic+control+of+immune+response+to+measles-mumps-rubella+vaccine&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Ovsyannikova%2C+Inna+G&rft.au=Pankratz%2C+V+Shane&rft.au=Vierkant%2C+Robert+A&rft.au=Jacobson%2C+Robert+M&rft.date=2006-03-01&rft.issn=0022-1899&rft.volume=193&rft.issue=5&rft.spage=655&rft_id=info:doi/10.1086%2F500144&rft_id=info%3Apmid%2F16453260&rft.externalDocID=16453260
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon